ATE473763T1 - Replizierende adenovirus-vektoren - Google Patents

Replizierende adenovirus-vektoren

Info

Publication number
ATE473763T1
ATE473763T1 AT02737279T AT02737279T ATE473763T1 AT E473763 T1 ATE473763 T1 AT E473763T1 AT 02737279 T AT02737279 T AT 02737279T AT 02737279 T AT02737279 T AT 02737279T AT E473763 T1 ATE473763 T1 AT E473763T1
Authority
AT
Austria
Prior art keywords
adenovirus
impairment
vectors
adenovirus vectors
virus
Prior art date
Application number
AT02737279T
Other languages
English (en)
Inventor
Andrea Amalfitano
Bradley Hodges
Dwight D Koeberl
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Application granted granted Critical
Publication of ATE473763T1 publication Critical patent/ATE473763T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02737279T 2001-06-04 2002-05-31 Replizierende adenovirus-vektoren ATE473763T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29591401P 2001-06-04 2001-06-04
PCT/US2002/017070 WO2002098466A1 (en) 2001-06-04 2002-05-31 Replicating adenovirus vectors

Publications (1)

Publication Number Publication Date
ATE473763T1 true ATE473763T1 (de) 2010-07-15

Family

ID=23139759

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02737279T ATE473763T1 (de) 2001-06-04 2002-05-31 Replizierende adenovirus-vektoren

Country Status (6)

Country Link
US (1) US6946126B2 (de)
EP (1) EP1418948B1 (de)
AT (1) ATE473763T1 (de)
DE (1) DE60237013D1 (de)
TW (1) TWI267552B (de)
WO (1) WO2002098466A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369985A1 (en) * 2002-01-18 2003-07-18 Duke University Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach
EP1587923B1 (de) 2003-01-22 2011-08-24 Duke University Verbesserte konstrukte zur expression lysosomaler polypeptide
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
EP1729817B1 (de) * 2004-03-30 2014-03-05 Industry-Academic Cooperation Foundation Relaxin-gen enthaltendes genverabreichungssystem und pharmazeutische zusammensetzung, die relaxin verwendet
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
CA2783010C (en) * 2009-12-08 2020-06-16 Memorial Sloan-Kettering Cancer Center Method and composition to increase radiation-induced tumor therapeutic effects
US8679478B2 (en) * 2010-10-04 2014-03-25 Duke University Methods of lysosomal storage disease therapy
US20140359799A1 (en) * 2011-12-23 2014-12-04 Case Western Reserve University Targeted gene modification using hybrid recombinant adeno-associated virus
EP3694998A1 (de) * 2017-10-12 2020-08-19 Freeline Therapeutics Limited Lebenszyklusdefekte adenovirus-helferviren, ihre herstellung und verwendung zur herstellung von raav
WO2020076820A2 (en) * 2018-10-09 2020-04-16 Nikegen, Llc Compositions and methods for preparing viral vectors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6019978A (en) * 1995-06-05 2000-02-01 The Wistar Institute Of Anatomy And Biology Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
CA2266342C (en) * 1996-09-25 2010-06-08 Novartis Ag Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors
US5998598A (en) * 1997-03-10 1999-12-07 The United States Of America, As Represented By The Department Of Health And Human Services Immunoadhesins and methods of production and use thereof
WO2000009153A1 (en) * 1997-10-29 2000-02-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
CN1342206A (zh) * 1998-08-28 2002-03-27 杜克大学 在IVa2,100K和/或preterminal protein序列上有缺失的腺病毒

Also Published As

Publication number Publication date
WO2002098466A1 (en) 2002-12-12
US20030109472A1 (en) 2003-06-12
TWI267552B (en) 2006-12-01
EP1418948A1 (de) 2004-05-19
DE60237013D1 (de) 2010-08-26
EP1418948B1 (de) 2010-07-14
US6946126B2 (en) 2005-09-20
EP1418948A4 (de) 2006-12-13

Similar Documents

Publication Publication Date Title
Gao et al. Human endogenous retroviruses in cancer: Expression, regulation and function
HUP9802217A2 (hu) Rekombináns MVA-vírus és alkalmazása
DE60237013D1 (de) Replizierende adenovirus-vektoren
FI964577A7 (fi) Alfavirusilmennysvektori
EP0757717A4 (de) Papillomavirus vakzine
HUP0203409A2 (hu) Gamma-interferon-konjugátumok
HUP0103598A2 (hu) Készítmények és eljárások WT1-specifikus immunterápiás alkalmazásra
AU2001259353A1 (en) Novel mutated form of arginine deiminase
WO2004027033A3 (en) Lentiviral vector-mediated gene transfer and uses thereof
NZ603348A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
ATE505480T1 (de) Knochenpolypeptid-1
JP2004501650A5 (de)
DK0851926T3 (da) Varianter af humant rekombinant gamminterferon (rhu-IFN-gamma) med forøget termisk stabilitet
DE60142519D1 (de) Dna-expressionsvektoren
IL174464A (en) Use of antisecretory factor for drug preparation
WO2002078631A3 (en) Improved conditionally replicating vectors for inhibiting viral infections
ATE386130T1 (de) Adenovirale vektoren für die gentherapie
EP1539937A4 (de) Verfahren zur vermehrung von adenovirus und damit produziertes virus
ATE272713T1 (de) Ehv-1 vektoren
ATE517999T1 (de) Adenovirale vektoren zur behandlung der erkrankungen
HUP9801681A2 (hu) Mutáns proteinek
FR2724320B1 (fr) Nouvel implant pour le traitement des maladies acquises
EA200600693A1 (ru) Пакующие клетки для рекомбинантных аденовирусов
ATE338826T1 (de) Rekombinante virale vektoren zur tetracyclinregulierbaren genexpression
JOP20240203A1 (ar) مولدات ضد ورمية، مركبات تتضمن مولدات الضد الورمية aurka او kras, tpx2 واستخداماتها

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties